XSHE
300171
Market cap1.81bUSD
Oct 09, Last price
15.96CNY
1D
0.06%
1Q
36.64%
Jan 2017
7.19%
IPO
45.89%
Name
Tofflon Science and Technology Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tofflon Science and Technology Group Co., Ltd., originally established in 1993 as Shanghai Tofflon Science and Technology Co., Ltd. and headquartered in Shanghai, China, serves as a global purveyor of sophisticated equipment for the pharmaceutical and biotechnology sectors. The company's diverse offerings encompass specialized machinery for injectable drug manufacturing, including automated systems for solution preparation, aseptic filling lines tailored for ampoules, vials, syringes, and powders, along with freeze dryers featuring automatic loading capabilities, barrier systems, and plastic packaging machines. Beyond equipment, Tofflon also supplies active pharmaceutical ingredients and provides essential quality control systems such as visual inspection, leak detection, and integrated combination units. Furthermore, Tofflon is a significant provider of bio-process equipment and comprehensive integrated systems. These solutions cover various stages, from medium and buffer preparation to cell/microbial cultivation, harvesting, diafiltration/ultrafiltration (DF/UF), purification, and final filling processes. The company also offers specialized laboratory services for lyophilization of injectables.
Key people
Xiaodong Zheng
Chairman of the Board, General Manager · since 2017
Dehua Lu
Chief Financial Officer · since 2023
Jinsheng Cheng
Deputy General Manager · since 2017
Huixing Tang
Deputy General Manager · since 2023
Haibin Zhang
Deputy General Manager, Director · since 2017
Xiaoyou Zheng
Deputy General Manager, Director · since 2011
Guoxing Zhao
Research & Development Director · since 2023
Yan Wang
Deputy General Manager, Secretary of the Board · since 2017
Yong Chen
Staff Elected Director · since 2026
Fangyao Du
Director · since 2026
Jianlin Yao
Deputy General Manager, Director · since 2026
Qiyu Zhang
Director · since 2026
Jinwang Zheng
Chief Technology Officer, Director · since 2023
Independent Director · since 2026
Yongchang Qiang
Independent Director · since 2020
Independent Director · since 2026
Independent Director · since 2026
Aimin Zhang
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||